Mirati Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Revenue
Product revenue, net
License and collaboration revenues
Total revenue
Operating expenses
Cost of product revenue
Research and development
Selling, general and administrative
Total operating expenses
Loss from operations
Other income (expense), net
Net loss before tax
Income tax expense
Net loss
Foreign currency translation adjustment
Unrealized loss on available-for-sale investments
Comprehensive loss
Basic net loss per share (USD per share)
Diluted net loss per share (USD per share)
Weighted average common shares outstanding, basic (shares)
Weighted average common shares outstanding, diluted (shares)

Comments